Daratumumab Market Overview
A monoclonal antibody called daratumumab that targets CD38 has become a transformational treatment for a variety of hematologic malignancies, most notably multiple myeloma (MM). The treatment of relapsed/refractory MM and newly diagnosed patients who are not eligible for transplant has been revolutionized by its exceptional efficacy, both when used alone and in...
Chinese
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek